On Monday, JPMorgan (NYSE:JPM) made an adjustment to the price target for Healthpeak Properties Inc (NYSE:DOC), increasing it to $24.00 from the previous target of $21.00.
The firm has decided to maintain a Neutral rating on the stock. This change comes as JPMorgan revises its model for the company ahead of its third-quarter results for the year 2024.
The adjustments made by the analyst are described as relatively minor, with a slight increase in the forecast for funds from operations (FFO) per share. For the year 2024, the FFO per share estimate has been raised by one cent to $1.79. Conversely, the estimate for 2025 has been decreased by one cent, bringing it down to $1.81 per share.
In other recent news, Healthpeak Properties has reported robust earnings results and strategic mergers. Scotiabank reaffirmed a Sector Outperform rating on Healthpeak shares, driven by the significant potential in the company's Lab segment. This led to an increase in the price target for Healthpeak shares to $24.00. The Lab segment's Net Operating Income (NOI) is expected to be a significant contributor to future earnings growth, with an annual NOI opportunity of $60 million from main development campuses.
Citi updated its price target for Healthpeak, increasing it to $22 while maintaining a Neutral stance. This adjustment was made following the company's second-quarter earnings report and revised operational, financing, and transaction assumptions. Baird also increased its price target for Healthpeak to $24.00, citing operational management strength, lab improvements, and merger synergies.
Healthpeak has also completed a merger with Physicians Realty (NYSE:DOC_OLD), bringing additional scale and tenant relationships, and fully acquired King Street Properties' minority stake in their joint venture, expanding Healthpeak's greater Boston portfolio to a total of 2.7 million square feet. RBC Capital and Evercore ISI raised their price targets for Healthpeak Properties to $25 and $24, respectively, maintaining Outperform ratings. T
InvestingPro Insights
As Healthpeak Properties Inc (NYSE:DOC) gears up for its third-quarter results for 2024, the InvestingPro platform provides additional context to JPMorgan's updated analysis. With a market capitalization of $16.01 billion, Healthpeak stands out as a significant player in its industry. The company's shares are currently trading at a high earnings multiple, with a P/E ratio of 46.89, which escalates to 75.31 when adjusted for the last twelve months as of Q2 2024. This high valuation is supported by a solid revenue growth of 13.99% during the same period, indicating an upward trajectory in the company's financial performance.
InvestingPro Tips highlight that Healthpeak has been successful in maintaining dividend payments for an impressive 40 consecutive years, a testament to its financial stability and commitment to shareholders. The dividend yield stands at a notable 5.31% as of the last recorded date, which is compelling for income-focused investors. Additionally, the company has experienced a large price uptick over the last six months, with a total return of 34.94%, showcasing strong recent market confidence.
For investors seeking further insights and analysis, the InvestingPro platform lists several additional tips on Healthpeak Properties Inc, including management's aggressive share buybacks and analysts' anticipation of sales growth in the current year. These insights, coupled with real-time data and metrics, provide a comprehensive view for those evaluating the company's stock. To explore these tips in detail, visit https://www.investing.com/pro/DOC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.